Additionally, early phase studies looking at a novel T-cell bispecific antibody targeting both Carcinoembryonic antigen (CEA) on tumor cells and CD3 on T-cells had shown evidence of anti-tumor response in mCRC patients following monotherapy regimes, and further response enhancement when anti-CEA/CD3 was combined with the anti-PD-L1 checkpoint inhibitor atezolizumab [47]. This evidence concerns the gene CEACAM5 and neoplasm.